Skip to main content
. 2021 Aug 5;10(16):e021459. doi: 10.1161/JAHA.121.021459

Figure 1. Cumulative incidence of mortality and hospitalization outcomes for patients discharged with sacubitril/valsartan vs an ACEI/ARB.

Figure 1

Curves reflect adjusted results in the form of directly adjusted cumulative incidence curves, which were derived from inverse‐probability‐of‐treatment‐weighted proportional hazards models. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; and HF, heart failure.